These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20345926)

  • 21. Cost of Parkinson's disease among Filipino patients seen at a public tertiary hospital in Metro Manila.
    Prado M; Jamora RD
    J Clin Neurosci; 2020 Apr; 74():41-46. PubMed ID: 31983646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and Economic Insights into Parkinson's Disease Hospitalization: A Comprehensive Study of 19,719 Inpatient Cases in Hubei Province, China.
    Liu W; Nie P; Zhang J; Zhou D; Zhang J; Chen J
    Neuroepidemiology; 2024; 58(4):237-246. PubMed ID: 38290491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of the health-related quality of life and economic impact of Parkinson's disease.
    Dowding CH; Shenton CL; Salek SS
    Drugs Aging; 2006; 23(9):693-721. PubMed ID: 17020395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug and treatment costs in Parkinson's disease patients in Sweden.
    Lökk J; Borg S; Svensson J; Persson U; Ljunggren G
    Acta Neurol Scand; 2012 Feb; 125(2):142-7. PubMed ID: 21470194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic burden of blindness and visual impairment in Germany from a societal perspective: a cost-of-illness study.
    Chuvarayan Y; Finger RP; Köberlein-Neu J
    Eur J Health Econ; 2020 Feb; 21(1):115-127. PubMed ID: 31493181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
    Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
    Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: an Italian cohort study.
    Winter Y; von Campenhausen S; Reese JP; Balzer-Geldsetzer M; Longo K; Spiga G; Boetzel K; Eggert K; Oertel WH; Dodel R; Barone P
    Neurodegener Dis; 2010; 7(6):365-72. PubMed ID: 20523028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cost-effectiveness of specialized nursing interventions for people with Parkinson's disease: the NICE-PD study protocol for a randomized controlled clinical trial.
    Radder DLM; Lennaerts HH; Vermeulen H; van Asseldonk T; Delnooz CCS; Hagen RH; Munneke M; Bloem BR; de Vries NM
    Trials; 2020 Jan; 21(1):88. PubMed ID: 31941538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimating the direct and indirect costs associated with Parkinson's disease.
    Rodríguez-Blázquez C; Forjaz MJ; Lizán L; Paz S; Martínez-Martín P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):889-911. PubMed ID: 26511768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health economic burden of patients with restless legs syndrome in a German ambulatory setting.
    Dodel R; Happe S; Peglau I; Mayer G; Wasem J; Reese JP; Giani G; Geraedts M; Trenkwalder C; Oertel WH; Stiasny-Kolster K
    Pharmacoeconomics; 2010; 28(5):381-93. PubMed ID: 20297866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Direct costs for Parkinson's treatment in private neurology practices in Berlin].
    Ehret R; Balzer-Geldsetzer M; Reese JP; Dodel I; Becker E; Christopher A; Friedrich H; Kraemer S; Lüer W; Müngersdorf M; Puzich R; Rohr A; Schultes-Platzek I; Siefjediers V; Tiel-Wilck K; Oertel WH; Dodel R
    Nervenarzt; 2009 Apr; 80(4):452-8. PubMed ID: 19252890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Parkinson's disease: cost-of-illness in an outpatient cohort].
    Reese JP; Winter Y; Balzer-Geldsetzer M; Bötzel K; Eggert K; Oertel WH; Dodel R; Campenhausen Sv
    Gesundheitswesen; 2011 Jan; 73(1):22-9. PubMed ID: 20229454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost effectiveness of pramipexole in Parkinson's disease in the US.
    Hoerger TJ; Bala MV; Rowland C; Greer M; Chrischilles EA; Holloway RG
    Pharmacoeconomics; 1998 Nov; 14(5):541-57. PubMed ID: 10344917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
    Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug costs for patients with Parkinson's disease in two different European countries.
    Vossius C; Gjerstad M; Baas H; Larsen JP
    Acta Neurol Scand; 2006 Apr; 113(4):228-32. PubMed ID: 16542161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cabergoline versus levodopa monotherapy: a decision analysis.
    Smala AM; Spottke EA; Machat O; Siebert U; Meyer D; Köhne-Volland R; Reuther M; DuChane J; Oertel WH; Berger KB; Dodel RC
    Mov Disord; 2003 Aug; 18(8):898-905. PubMed ID: 12889079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis.
    Martinez-Martín P; Rodriguez-Blazquez C; Paz S; Forjaz MJ; Frades-Payo B; Cubo E; de Pedro-Cuesta J; Lizán L;
    PLoS One; 2015; 10(12):e0145310. PubMed ID: 26698860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
    Pålhagen SE; Sydow O; Johansson A; Nyholm D; Holmberg B; Widner H; Dizdar N; Linder J; Hauge T; Jansson R; Bergmann L; Kjellander S; Marshall TS
    Parkinsonism Relat Disord; 2016 Aug; 29():17-23. PubMed ID: 27318707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost of depression in Europe.
    Sobocki P; Jönsson B; Angst J; Rehnberg C
    J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.